Kay E¹, Hawramee S, Pollani S, Mandel ED. JAAPA. 2019 Mar;32(3):38-42. doi: 10.1097/01.JAA.0000553384.82884.b8.

Author information

1 At the time this article was written, Emelia Kay, Sham Hawramee, and Stephen Pollani were students in the PA program at Pace University-Lenox Hill Hospital in New York City. Ms. Kay now practices at Arizona Digestive Health in Sun City, Ariz. Ms. Hawramee practices internal medicine at Montefiore Hospital in the Bronx, N.Y. Mr. Pollani practices primary care. Ellen D. Mandel is a clinical professor in the Department of PA Studies at Pace University-Lenox Hill Hospital in New York City. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Abstract

Irritable bowel syndrome (IBS) is a chronic functional disorder with no organic cause. Risk factors are multifactorial and treatment typically consists of antimotility or stimulant laxatives and antidepressants. This article reviews several newer areas of interest: probiotics, fecal microbiota transplant, a low FODMAP diet, and cognitive behavioral therapy.